Govt opening up access to COVID-19 antiviral due to expiry dates
The PBS criteria for patients aged 50-59 and those aged 60-69 will be aligned.
Patients aged 50-59 with one chronic condition will be eligible for PBS-funded nirmatrelvir-ritonavir to use up a stockpile of the COVID-19 treatment before it expires.
Currently, patients in this age range with COVID-19 require two risk factors to be eligible for PBS-funded nirmatrelvir-ritonavir (Paxlovid), while those aged 60-69 require one risk factor.
